Brief Introduction

Shanghai MicroPort Endovascular MedTech Co., Ltd. (“Endovastec™”) was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise and the first batch of Specialized and New “Little Giant” Enterprise in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.

Endovastec™ is committed to develop, manufacturing, and sale of aortic and peripheral vascular intervention devices, and its main products are thoracic and abdominal aortic stent graft, stent in surgical operation, peripheral vascular stent and peripheral vascular balloon dilatation catheter, etc. Endovastec™ developed successfully the first domestic abdominal aortic stent graft and its stent in surgical operation is the only device that has been approved to be applied in thoracic aortic dissection procedures in China. In addition, Endovastec™ Castor® by self-developed is the first approved branched aortic stent graft in the world. At present, Endovastec™ 5 self-developed products has been approved by the national “Special Approval Procedure of Innovative Medical Device”, being in a leading position in the industry..

Endovastec™ always pays attention to each user's personal feelings, with the vision of providing personalized treatment programs and services to patients with aortic and peripheral diseases. Through continuous innovation, we provide our doctors with the best inclusive medical solutions that can save and reshape patients' lives or improve their quality of life, and make a contribution to society.

Company Overview

Full name Shanghai MicroPort Endovascular MedTech Co., Ltd.
Abbreviations /
Code 688016
Founded 2012.8.17
Listing 2019.7.22
Domicile Shanghai
Website www.endovastec.com
Email irm@endovastec.com
STAR Theme Biomedicine
CSRCSector Manufacturing
Has weighted voting rights structure? No

Financials

Highlights

  2018 2017 2016
Earnings Per Share 1.68 - -
R&D expenditure as a % of operating revenue 20.71% 27.27% 32.85%
Operating Revenue 231.13 165.13 125.33
Net Income 90.65 63.39 41.11

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 231.13 165.13 125.33
Operating Costs 134.43 92.47 80.47
Operating Income 104.85 73.92 44.85
Pretax Income 104.85 74.04 47.82
Income Tax 14.20 10.65 6.71
Net Income 90.65 63.39 41.11

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Assets
Current Assets-Total 116.03 88.47 76.13
Non-current Assets-Total 152.79 135.79 112.47
Total Assets 268.82 224.26 188.60
Liabilities
Current Liabilities-Total 39.20 25.45 59.14
Non-current Liabilities-Total 13.47 10.79 6.08
Total Liabilities 52.66 36.24 65.22
Stockholder's Equity
Share Capital 150.33 114.10 112.84
Retained Profits 65.82 73.92 10.54
Minority Interests - - -
Total Owners' Equity 216.16 188.02 123.38

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating 106.85 69.36 30.13
Net Cash Flows-Investing -24.79 -27.84 -31.97
Net Cash Flows-Financing -64.00 -37.40 16.71

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
MicroPort Endovascular CHINA Corp.Limited 32.90 45.71%
上海联木企业管理中心(有限合伙) 6.09 8.46%
上海虹皓投资管理中心(有限合伙) 5.29 7.36%
上海阜釜企业管理咨询中心(有限合伙) 3.79 5.27%
上海久深股权投资基金合伙企业(有限合伙) 2.63 3.65%
国泰君安证券资管-南京银行-国泰君安君享心脉1号集合资产管理计划 1.54 2.14%
中金佳泰贰期(天津)股权投资基金合伙企业(有限合伙) 1.50 2.09%
上海张江科技创业投资有限公司 1.32 1.84%
国泰君安证裕投资有限公司 0.87 1.20%
华菁证券投资有限公司 0.87 1.20%
22 Jul 2019

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.